Clinical trial
TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients
NCT00415909 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00415909 |
|---|---|
| Title | TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients |
| Official title | Phase II "Proof of Concept" Study of TALL-104 (MHC Non-Restricted Cytotoxic T-Cell Line) and Imatinib Mesylate (Gleevec) in Chronic Myelogenous Leukemia in Chronic Phase |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Abiogen Pharma Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | Imatinib Mesylate (IM), TALL-104 cells |
| Enrollment | 3 |
| Start date | Dec 1, 2006 |
| Primary completion | May 1, 2013 |
| Completion | May 1, 2013 |
| First posted | Dec 25, 2006 |
| Last update posted | Jun 30, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: